Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dolby Laboratories (DLB) EBT (2016 - 2025)

Dolby Laboratories' EBT history spans 17 years, with the latest figure at $71.6 million for Q4 2025.

  • For Q4 2025, EBT fell 16.79% year-over-year to $71.6 million; the TTM value through Dec 2025 reached $289.0 million, down 9.02%, while the annual FY2025 figure was $303.5 million, 2.88% down from the prior year.
  • EBT reached $71.6 million in Q4 2025 per DLB's latest filing, up from $41.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $121.7 million in Q1 2024 to a low of $9.0 million in Q3 2023.
  • Average EBT over 5 years is $67.0 million, with a median of $59.4 million recorded in 2021.
  • Peak YoY movement for EBT: crashed 70.84% in 2023, then soared 561.29% in 2024.
  • A 5-year view of EBT shows it stood at $91.4 million in 2021, then grew by 9.34% to $100.0 million in 2022, then dropped by 19.15% to $80.8 million in 2023, then increased by 6.46% to $86.1 million in 2024, then fell by 16.79% to $71.6 million in 2025.
  • Per Business Quant, the three most recent readings for DLB's EBT are $71.6 million (Q4 2025), $41.7 million (Q3 2025), and $55.5 million (Q2 2025).